Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…

BySenior EditorApril 13, 2023

INSIGHTS+

Disease of the Month: Hemophilia

Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures To continue the series for disease of the month, PharmaShots brings this month a summary…

BySenior EditorApril 11, 2023

TOP 20

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…

ByPrince GiriMarch 29, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2022

The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4B The third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

BySenior EditorSeptember 29, 2022

VIEWPOINTS

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk

In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…

BySenior EditorOctober 15, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021 Additionally, last year in 2020, the US FDA…

BySenior EditorJuly 15, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021 Additionally, last year in 2020, the US FDA…

BySenior EditorJuly 7, 2021

TOP 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

ByPrince GiriJuly 17, 2020

TOP 20

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…

ByPrince GiriApril 24, 2020

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Disease of the Month: Hemophilia

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

PharmaShots’ Key Highlights of Third Quarter 2022

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk

Insights+: The US FDA New Drug Approvals in June 2021

PharmaShots’ Key Highlights of Second Quarter 2021

Top 20 Prescription Drugs Based on 2019 Revenue

Top 20 BioPharma Companies based on 2019 Total Revenue

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Contact US

FOLLOW US